Sep 22, 2025 8:00 am EDT Grace Therapeutics Pivotal Phase 3 STRIVE-ON Safety Trial Presented at 2025 Neurocritical Care Annual Meeting
Sep 18, 2025 8:30 am EDT Grace Therapeutics Granted Sixth U.S. Patent Covering I.V. Dosing Regimen for GTx-104
Sep 4, 2025 8:00 am EDT Grace Therapeutics Announces Presentation at The H.C. Wainwright 27th Annual Global Investment Conference
Aug 27, 2025 8:00 am EDT Grace Therapeutics Announces U.S. Food and Drug Administration Acceptance for Review of New Drug Application for GTx-104
Aug 12, 2025 8:00 am EDT Grace Therapeutics Announces First Quarter 2026 Financial Results, Provides Business Update
Jun 25, 2025 8:00 am EDT Grace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104
Jun 23, 2025 8:00 am EDT Grace Therapeutics Announces 2025 Fiscal Year-End Results, Provides Business Update
Apr 9, 2025 8:00 am EDT Grace Therapeutics Announces Alignment with the FDA Supporting the Planned NDA Submission for GTx-104
Feb 25, 2025 8:00 am EST Grace Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference